Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
28.58
+1.29 (4.73%)
At close: Apr 24, 2026, 4:00 PM EDT
28.63
+0.05 (0.17%)
After-hours: Apr 24, 2026, 5:31 PM EDT
Pharvaris Employees
Pharvaris had 129 employees as of December 31, 2025. The number of employees increased by 21 or 19.44% compared to the previous year.
Employees
129
Change
21
Growth
19.44%
Revenue / Employee
n/a
Profits / Employee
-$1,599,167
Market Cap
1.87B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 129 | 21 | 19.44% |
| Sep 30, 2025 | 118 | 26 | 28.26% |
| Jun 30, 2025 | 114 | 31 | 37.35% |
| Mar 31, 2025 | 119 | 36 | 43.37% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Sep 30, 2024 | 92 | 22 | 31.43% |
| Jun 30, 2024 | 83 | 15 | 22.06% |
| Mar 31, 2024 | 83 | 17 | 25.76% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Sep 30, 2023 | 70 | 14 | 25.00% |
| Jun 30, 2023 | 68 | 21 | 44.68% |
| Mar 31, 2023 | 66 | 25 | 60.98% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Sep 30, 2022 | 56 | 39 | 229.41% |
| Jun 30, 2022 | 47 | 30 | 176.47% |
| Mar 31, 2022 | 41 | 27 | 192.86% |
| Dec 31, 2021 | 34 | 20 | 142.86% |
| Jun 30, 2021 | 17 | - | - |
| Mar 31, 2021 | 14 | 11 | 366.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Galapagos NV | 558 |
| Vericel | 398 |
| Syndax Pharmaceuticals | 298 |
| Harmony Biosciences Holdings | 293 |
| Stoke Therapeutics | 170 |
| Innoviva | 159 |
| Inhibrx Biosciences | 110 |
PHVS News
- 6 days ago - Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference - GlobeNewsWire
- 24 days ago - Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology - GlobeNewsWire
- 6 weeks ago - Pharvaris Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology - GlobeNewsWire
- 6 weeks ago - Pharvaris Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 - GlobeNewsWire
- 2 months ago - Pharvaris Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts